Twist Bioscience (NASDAQ:TWST) Stock Price Target Lowered at Leerink Partners

Twist Bioscience (NASDAQ:TWST) had its target price cut by Leerink Partners from $190.00 to $175.00 in a report published on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

TWST has been the subject of a number of other research reports. Robert W. Baird cut their price target on shares of Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating for the company in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, September 21st. Piper Sandler raised their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. BWS Financial reiterated a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. Finally, Canaccord Genuity Group lowered their price target on Twist Bioscience from $205.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Twist Bioscience has an average rating of “Hold” and a consensus target price of $141.00.

Twist Bioscience Trading Down 2.3%

Shares of Twist Bioscience stock opened at $111.60 on Friday. Twist Bioscience has a 12-month low of $23.30 and a 12-month high of $219.71. The stock has a market cap of $7.00 billion, a P/E ratio of -53.40 and a beta of 2.25. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $150.23 and its 200-day moving average is $93.07.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.07. The business had revenue of $126.64 million during the quarter, compared to analysts’ expectations of $123.55 million. Twist Bioscience had a negative net margin of 28.34% and a negative return on equity of 27.53%. Twist Bioscience’s quarterly revenue was up 26.7% compared to the same quarter last year. Equities research analysts predict that Twist Bioscience will post -1.52 earnings per share for the current fiscal year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 9,514 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,797,004.32. Following the completion of the sale, the insider directly owned 63,789 shares in the company, valued at $12,048,466.32. This trade represents a 12.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily Leproust sold 356,546 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $157.99, for a total value of $56,330,702.54. Following the sale, the chief executive officer owned 620,589 shares of the company’s stock, valued at approximately $98,046,856.11. This represents a 36.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 495,279 shares of company stock worth $80,489,387 in the last quarter. Corporate insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new stake in shares of Twist Bioscience during the first quarter worth $31,000. Root Financial Partners LLC bought a new position in Twist Bioscience in the 3rd quarter valued at about $33,000. Steward Partners Investment Advisory LLC raised its position in Twist Bioscience by 99.0% during the third quarter. Steward Partners Investment Advisory LLC now owns 203 shares of the company’s stock valued at $39,000 after purchasing an additional 101 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after buying an additional 453 shares in the last quarter. Finally, Fifth Third Bancorp bought a new position in shares of Twist Bioscience in the first quarter worth about $54,000.

Key Headlines Impacting Twist Bioscience

Investors following TWST have been watching these headlines:

• Positive Sentiment: Fiscal Q4 revenue rose about 27% year over year to $126.6 million, beating consensus, while the $0.32-per-share loss was narrower than analysts expected. AI drug-discovery revenue totaled $59.1 million for fiscal 2026. Article: Twist Bioscience: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Fiscal Q1 2027 revenue guidance of $130 million–$132 million is above the $126.3 million consensus estimate. Article: Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
• Negative Sentiment: Leerink Partners cut its price target to $175 from $190, TD Cowen to $137 from $190, and Baird to $135 from $187. Each maintained a positive rating—outperform or buy—but the reductions indicate more cautious valuation expectations. Leerink Partners ratings

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.